Daawaynta kansarka ayaa dhawaan isu beddeshay hab aad u wanaagsan; Mid ka mid ah horumarka ugu muhiimsan ayaa lagu helay hababka daaweynta immunotherapy ee heerka gacanta. B-Cell Leukemia waxay ka duwan tahay kansarka dhiigga intiisa kale sababtoo ah arrimaheeda gaarka ah iyo jawaabaha daaweynta. Xaaladdan, gaar ahaan marka ay keento bararka B lymphocytes ee dhiigga, waxay kicin doontaa habab cusub oo looga fikiro la dagaallanka cudurka iyo hagaajinta natiijooyinka bukaannada. Cilmi-baaris joogto ah ayaa la sameeyaa si loo soo saaro doorarka cusub ee B-Cell ee daaweynta daawaynta ku salaysan pathology-ga shakhsi ahaaneed ee loo habeeyey si looga shaqeeyo hababka hoos yimaada cudurka. Beijing BIOOCUS Biotech Ltd. waxay ku qumman tahay xagga hore ee isbeddelkan kobcinta, iyada oo fulinaysa cilmi-baarista iyo horumarinta immunotherapies-ka gacanta, oo haddii kale waxay leedahay isku dayo aan waxtar lahayn si ay ula kulanto caqabadaha B-Cell Leukemia. Shirkadda hormuudka ka ah bayoolajiga ee Shiinaha waxay sidoo kale ku faantaa inay tahay shirkad silsilad-qiimo leh leh oo leh xarun cilmi-baaris oo iskeed u leh, xarunta GMP, madal CDMO, iyo madal wareejinta tignoolajiyada. Ballanqaadkayaga daawaynta B-Cell Leukemia wuxuu dhaafsiisan yahay heerarka badbaadada; Waxay ku fidsan tahay in daawaynta laga dhigo waayo-aragnimo aad u wanaagsan oo loogu talagalay bukaannada, oo leh xeelado cusub iyo kuwo la gaaryeelay.